CRSP

#1281
CRISPR Therapeutics AG - Common Shares
55.9 3 USD
-0.80%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
55.48
56.13
Годовой диапазон
35.48
78.48
Дневное изменение
-0.80%
Месячное изменение
+8.98%
6-месячное изменение
+6.94%
Годовое изменение
+51.57%
Предыдущее закрытие
56.3 8
Open
55.6 5
Low
55.4 8
High
56.1 3
Volume
345
Открыть полный график Full chart

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 5.39 B
  • Employee 393
  • Founded 2013
  • CEO Samarth Kulkarni
  • Website www.crisprtx.com
  • Headquarter Switzerland
  • FIGI UNKNOWN
  • Industry Биотехнологии
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-7.71
Коэффициент цена/денежный поток
1 062.57

CRISPR Therapeutics AG - Common Shares

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023.

Новости